CHF Solutions, Inc (CHFS)

[TheFinalCD]

1.45 bearpole

[TheFinalCD]

looks like the bots are using the bollies on the 15 MTF
because it has been riding that very well

[TheFinalCD]

i traded 3x all green trades, now bidding low 1.25

just incase

1.48 now

[crudeoil24]

LOL...Chef's Delight.

[dirtydozen911]

CHFS...….or is that short for "chiefs"...….perfect symbol......Cherokee nation .."trail of tears"....hahahahah there will be some tears at 4 pm on this pig hahaha …. GLTA..

big..long ..red candle commeth!!

[Imarket13]

Couldve been really nice .. they had to dilute on us lol..ETA see if it has another bounce

[TheFinalCD]

lol maybe it just looked good @ 1.64 the tripped and fell to 1.48

I think 1.20's will be a good buy

lets see

[dirtydozen911]

this pig`s gonna give it all back...…$1.10 end of day ??

great volume , but bow-tie on a pig!!

[TheFinalCD]

agree, if can get back over 1.70, can go $2

[europtiger]

Looking good to go again

[TheFinalCD]

dunno, but Inst Own 15.50%, and shorts vs bull funds wash trading like a mofo

so it trades multiple x the float

thats this corrupted market

so hard to tell if its dilution

[Imarket13]

Dilution?

[TheFinalCD]

heck yeah especially trading 10x the float= https://finviz.com/quote.ashx?t=CHFS

[Imarket13]

Shouldve been like 3 bucks by now with this volume.

[TheFinalCD]

BACK TO 1.60 THAT QUICJ FROM 1.43

CHFS

[europtiger]

Just rebought here

[TheFinalCD]

touched 1.47,,,,,, 1.45 is middle bollie on the 10min

[Imarket13]

Looks like they diluting

[whytestocks]

News: $CHFS CHF Solutions, Inc. Announces Sales Force Realignment To Increase Focus On Cardiac Surgery And Eventually Pediatrics

EDEN PRAIRIE, Minn., Nov. 01, 2019 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (Nasdaq: CHFS), a medical device company focused on developing, manufacturing and commercializing a clinically proven solution for diuretic-resistant patients suffering from fluid overload, announced a sales force re...

Got this from CHFS - CHF Solutions, Inc. Announces Sales Force Realignment To Increase Focus On Cardiac Surgery And Eventually Pediatrics

[TheFinalCD]

1.53 looks bottom on that dip got some 1.59

[Guelly]

I saw this this am and rode it to 1.6, should’ve just held till next week, I’ll buy again if it dips, looking great however, such a huge profit potential here, damm! Good luck to those holding

[JOHNNY-VEGAS]

RUNNING OUT OF FUEL?

[europtiger]

Churn between 1,60-199 then leg up

[Snowman2]

And again

[Snowman2]

Some excitement for Friday morning

[Snowman2]

All that green

[Snowman2]

Cool off then resume this one's a runner

[Snowman2]

Oh yea

[TheFinalCD]

new highs

CHFS

[Snowman2]

Around 5 dollars

[Snowman2]

Wow

[europtiger]

I guess we see some churn... and then a leg to 2

[TheFinalCD]

wow CHFS


looks like it wants 2's

[europtiger]

And way more... it could ;)

[Imarket13]

Could hit 2.00 plus

[europtiger]

What a beast

[europtiger]

Yeah super sweet float... may 1,80+ today... could also turn into a real monster

[crudeoil24]

Nice going bud! > moving up like rocketship.

[crudeoil24]

Nice going bud! > moving up like rocketship.

[europtiger]

4,5 Milli volume First 5 minutes lol

[europtiger]

Woooowzaaaa,moving strong

[europtiger]

Super low floater exploding

[europtiger]

Got 1,29

[crudeoil24]

Interesting on CEO John Erb. > Today's news is powering CHFS up in PM.

[whytestocks]

News: $CHFS Multi-Center, Retrospective Study Evaluates Use of Ultrafiltration Therapy with Aquadex FlexFlow® System in Pediatric Patients

EDEN PRAIRIE, Minn., Sept. 24, 2019 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (Nasdaq:CHFS) today announced the publication of a multi-center, retrospective study in the Clinical Journal of the American Society of Nephrology 1 evaluating the use of hemofiltration and ultrafiltration therapy ...

Got this from CHFS - Multi-Center, Retrospective Study Evaluates Use of Ultrafiltration Therapy with Aquadex FlexFlow® System in Pediatric Patients

[Golden Cross]

Multi-Center, Retrospective Study Evaluates Use of Ultrafiltration Therapy with Aquadex FlexFlow® System in Pediatric Patien...
Print
Alert
CHF Solutions (NASDAQ:CHFS)
Intraday Stock Chart
Today : Tuesday 24 September 2019

Click Here for more CHF Solutions Charts.
CHF Solutions, Inc. (Nasdaq:CHFS) today announced the publication of a multi-center, retrospective study in the Clinical Journal of the American Society of Nephrology1 evaluating the use of hemofiltration and ultrafiltration therapy with the company’s Aquadex FlexFlow system in pediatric patients. The Aquadex FlexFlow system is not yet cleared by FDA for use in pediatric patients.
The study, titled “Kidney Support in Children Using an Ultrafiltration Device,” included 117 patients in three weight categories: <10 kgs; 10-20 kgs; and >20 kgs, suffering from volume overload, acute kidney injury or end-stage kidney disease. All patients across the three weight categories were treated with the Aquadex FlexFlow system, using one of the following three modalities: slow continuous ultrafiltration (SCUF); continuous veno-venous hemofiltration (CVVH); or prolonged intermittent kidney replacement therapy, based on patient condition.

The primary outcome was survival to the end of therapy. In patients weighing over 20 kgs (n=32), 97% survived to the end of therapy. In patients weighing between 10-20 kgs (n=13), 100% survived to the end of therapy. In patients weighing under 10 kgs (n=72), 60% survived to the end of therapy.

“We report the first multi-center experience in pediatrics in which we use an ultrafiltration device to provide kidney support therapy in younger patients," said David Askenazi, M.D., M.S.P.H., Professor of Pediatrics at the University of Alabama Birmingham/Children’s of Alabama. “For many of the types of patients in the study, available therapies require very high relative extracorporeal blood volumes, which can be challenging. With the use of an ultrafiltration device with a small blood volume, we were able to initiate therapy with excellent hemodynamic stability.”

As previously announced, the company will be hosting a conference call and webcast with investigators from the study tomorrow, September 25, at 1:00 pm Eastern Time. To access the live webcast, please visit the Investors page of the CHF Solutions website at http://ir.chf-solutions.com or access the webcast directly at http://ir.chf-solutions.com/events. Alternatively, you may access the live conference call by dialing [phone] (U.S.) or [phone] (international) and using conference ID: 6985754. An audio archive of the webcast will be available following the call on the Investor page at http://ir.chf-solutions.com/events.

About CHF Solutions
CHF Solutions, Inc. (Nasdaq:CHFS) is a medical device company focused on developing, manufacturing and commercializing the Aquadex FlexFlow system for aquapheresis therapy. The Aquadex FlexFlow system is a clinically proven therapy that provides a safe, effective, and predictable method of removing excess sodium and fluid from patients suffering from fluid overload. The Aquadex FlexFlow system is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies. CHF Solutions expects to submit an application to the FDA requesting a modification to the 510(k) clearance for the Aquadex FlexFlow system to include pediatric patients above 20kg in the near future. The company is dedicated to changing the lives of patients suffering from fluid overload through science, collaboration, and innovative. CHF Solutions is a Delaware corporation headquartered in Minneapolis, Minnesota with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the Nasdaq Capital Market since February 2012.

[ROCKHard]

Wow, Erb and Drayton are two thieves. They are in this for themselves and maybe a few close ties. Investors they've used and abused... I believe everyone who held here since SSH change of name and direction has lost -99% on top of the SSH losses of probably another -99%.... all the while they've taken HUGE SALARIES and other means of screwing Investors out of money. I would not put it past them if they are in with shorting the stock indirectly because this is their character... shysters in sheep clothing. They should be JAILED.

Here's Some Projections based off facts and Proof:

See Heinz yahoo mb under CHFS postings....

https://prnt.sc/nm2rmr

Heinz4 months ago
you can imagine how many Shares they "must print" and how many resplits they Need to Keep nasdaq listing. Now 2 Mio. Shares outstanding. Even if share Price would remain on 3.50 (which is 100% not realistic), they must "print" arround 80 mio. Shares... 80 mio. / 2 = dillution 40 = 3.50 / 40 = 0.09 share price. And this is best case Szenario. Only if they do it like this the Company would survive. Actually this Company with 5 mio. turnover and arround 15-20 mio. loss each year is bancrupt without the System of resplit and printing new Shares after again and again..

[JohnConnor67]

CHFS looks like a nice play right now. Only 600 000 shares available

[jonnyvs]

Looking good here again

[whytestocks]

News: $CHFS CHF Solutions to Exhibit at The International Society for Heart and Lung Transplantation 2019 Annual Meeting and Scientific Sessions

EDEN PRAIRIE, Minn., March 28, 2019 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), today announced it will be exhibiting at the 2019 Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation (ISHLT) on April 3-6, 2019 at the Lowes Meeting Comp...

In case you are interested https://marketwirenews.com/news-releases/chf-solutions-to-exhibit-at-the-international-society-for-heart-and-lung-transplantation-2019-annual-meeting-and-scientific-sessions-7906018.html